1-磷酸鞘氨醇受体

1-磷酸鞘氨醇(sphingosine-1-phosphate,S1P)对动脉粥样硬化等心血管疾病的发生发展具有重要作用。最近研究发现S1P在不同细胞发挥的生物学效应由其受体(sphingosine-1-phosphate receptor,S1PR)介导,以S1PR及其信号机制为基础的研究及治疗策略成为新的研究热点。本文主要综述S1PR的功能、信号通路及对心血管疾病的影响,为心血管疾病的预防和诊疗提供新的靶点。     

鞘氨醇-1-磷酸与免疫细胞的调节

鞘氨醇-1-磷酸（sphingosine-1 phosphate,S1P）是来源于鞘脂代谢途径的多效性信号分子,其代谢受到多种因素调控。S1P由细胞内的鞘氨醇激酶（sphingosine kinases,SphKs）催化鞘氨醇的磷酸化而合成,可通过转运蛋白释放至细胞外。S1P可通过在胞外结合其特异性G蛋白偶联受体及胞内作用而调节多种重要生物学效应。作为细胞外介质和细胞内信使,S1P在免疫系统中也发挥重要的调节作用。S1P参与免疫细胞的迁移、增殖、分化及死亡细胞清除等过程。本文对S1P的代谢以及其对于免疫细胞的调节作用进行综述。     

鞘氨醇激酶-磷酸鞘氨醇轴在血管生成相关性疾病中的作用

血管生成是指在原有血管的基础上形成新血管的过程.病理性血管生成是癌症、心血管类疾病和视网膜病变等一系列疾病的标志.1-磷酸鞘氨醇(sphingosine-1-phosphate,S1P)是一种信号脂质,由鞘氨醇激酶(sphingosine kinases,SPHK)合成,通过5种G蛋白偶联受体(sphingosine-...     

1- 磷酸鞘氨醇受体调节剂的研发现状

1- 磷酸鞘氨醇（S1P）具有多种生物学功能,S1P 受体（S1PR）调节剂可以用于治疗多种免疫性疾病。芬戈莫德是首个上市的S1PR 调节剂,用于治疗多发性硬化症（MS）,2015 年销售额达到27 亿美元。药渡网数据显示：目前全球有14 个S1PR 调节剂进入临床,适应证包括MS、银屑病、类风湿性关节炎和炎症性肠病等。国内目前针对S1PR 靶点的药物有1 个新药奥芬米洛已获批临床,另1 个新药CBP-307 处于临床在审评阶段。简介S1PR 的生物学功能和S1PR 调节剂在国内外的开发情况,为靶向S1PR 的药物开发提供参考。     

鞘氨醇-1-磷酸的定量测定——一种新的竞争性结合方法

鞘氨醇-1-磷酸（SPP）是重要的细胞第二信使,影响细胞的生长和死亡.通过培养和收集转染SPP受体-EDG-1的HEK293细胞,与标记及非标记SPP共孵育,利用它们与HEK293细胞的竞争性结合,测定细胞、血清和组织中SPP含量.该法无需特殊仪器,可以测到皮摩尔水平的低含量,批间差异小于15%（6次）.     

鞘氨醇激酶1和1-磷酸鞘氨醇受体2在癫痫大鼠海马组织中表达的变化*

目的:检测鞘氨醇激酶1 (SphK1)和1-磷酸鞘氨醇受体2 (S1PR2) 在癫痫大鼠海马中的表达,探讨SphK1和S1PR2在癫痫中的作用机制。方法:成年雄性SD大鼠108只,随机分为对照(Control)组(n=48)和癫痫(PILO)组(n=60)。癫痫组腹腔注射氯化锂(127 mg/kg),18～20 h后注射匹罗卡品,首剂量为30 mg/kg,发作＜IV级的大鼠重复注射匹罗卡品(10 mg/kg);对照组给予等剂量的生理盐水代替匹罗卡品。根据造模后观察时间和行为学改变,随机分为3个大组,6个亚组:急性期组(E6 h、E1 d、E3 d)、潜伏期组(E7 d)和慢性期组(E30 d、E56 d),每个亚组中对照大鼠和癫痫大鼠各8只。每组取4只大鼠麻醉取海马,另4只取大脑组织。运用Western blot检测SphK1、S1PR2在大鼠海马组织中的表达变化,免疫荧光检测星形胶质细胞活化增生情况及SphK1、S1PR2在星形胶质细胞中的定位表达。结果:与Control组比较,SphK1在造模后急性期(E3 d)、潜伏期(E7 d)和慢性期(E30 d、E56 d)海马中的表达均明显升高(P＜0.05或P＜0.01);S1PR2在急性期(E3 d)、潜伏期(E7 d)和慢性期(E30 d、E56 d)海马组织中的表达均明显下降(P＜0.05或P＜0.01);癫痫大鼠(E7 d)海马星形胶质细胞活化、增生明显(P＜0.05),SphK1和S1PR2在E7d的表达到位为海马星形胶质细胞中。结论:SphK1和S1PR2可能通过调控海马星形胶质细胞活化增生和影响神经元兴奋性参与了癫痫的发病。     

脂质活性信号分子鞘氨醇-1-磷酸及其生物学特性

鞘氨醇-1-磷酸(sphingosine-1-phosphate,S1P)是目前颇受关注的脂质信号分子.体内S1P主要由红细胞内鞘氨醇激酶催化鞘氨醇合成,后经由ATP结合盒式转运子释放入血浆.血浆S1P超过半数存在于高密度脂蛋白和血清白蛋白上.S1P可通过直接胞内作用和激活其特异性G蛋白偶联受体产生多种重要生物学效应.S1P1-5型受体在体内各类型组织和细胞表达水平不同,参与包括细胞增殖、存活、迁移等多种生物学过程.     

1-磷酸鞘氨醇对豚鼠心室肌动作电位和收缩力的影响

目的：研究1-磷酸鞘氨醇（S1P）对豚鼠心室肌动作电位（AP）和心肌收缩力（CF）的影响。方法：实验采用标准玻璃微电极细胞内记录技术记录心室肌细胞动作电位（AP）肌力换能器记录心肌收缩力（CF）。结果：①应用0．1μmol／LS1P后心室肌动作电位幅度（APA）和时程（APD）与应用SIP前比较差异无显著性,而应用1．0μmol／LS1P,10μmol／LS1P后心室肌动作电位的幅度（APA）与应用S1P前比较明显降低而动作电位的时程（APD）与应用S1P前比较明显延长（P〈0．01）。②应用1．0μmol／LS1P和10μmol／LSIP后心室肌的CF与给药前相比明显增强（P〈0．01）,应用0．1μmol／LS1P后心室肌的CF与给药前比较差异无显著性（P〉0．05）。而加入S1P特异性G蛋白耦联内皮细胞分化基因（EDG）受体阻断剂苏拉明后,S1P的上述作用与给药前比较差异无显著性（P〉0．05）。结论：S1P可以降低心室肌动作电位幅值延长动作电住时程,增加心室肌收缩力,并且是通过其特异性的G蛋白耦联内皮细胞分化基因（EDG）受体介导而产生这些作用,有一定的剂量依赖性.     

植物体内的鞘氨醇-1-磷酸(S1P)

鞘氨醇-1-磷酸（S1P）在植物体内也可作为一种信号分子参与ABA介导的保卫细胞信号转导过程,这一途径和异三聚体G蛋白相耦联。文章对此问题的研究进展作了介绍。     

1-磷酸鞘氨醇在肾脏纤维化中的作用及其调控

肾脏纤维化是原发或继发性肾脏病持续进展至终末期肾病的共同病理过程。1-磷酸鞘氨醇是一种具有生物活性的神经鞘脂类代谢物,参与组织纤维化的发生。研究发现,1-磷酸鞘氨醇在成纤维细胞转分化为肌成纤维细胞过程以及纤维化早期阶段炎症反应的诱导中发挥着关键作用。本文主要介绍1-磷酸鞘氨醇在肾脏纤维化中的作用及其调控,旨在更进一步认识肾脏纤维化发病机制,为肾脏纤维化疾病的预防及治疗提供新的靶向。     

Sphingolipid-to-glycerophospholipid conversion in SPL-null cells implies the existence of an alternative isozyme

Sphingosine-1-phosphate (S1P) lyase catalyzes the cleavage of the bioactive lipid molecule S1P to phosphoethanolamine and hexadecenal, both of which are utilized as glycerophospholipid precursors. Until now, only one gene, SPL, has been identified as encoding a S1P lyase. In the present study, SPL-null F9 cells were able to convert radiolabeled dihydrosphingosine to glycerophospholipids, albeit at much lower efficiency than parent cells. Lysates prepared from the SPL-null cells exhibited weak but significant dihydrosphingosine-1-phosphate lyase activity in vitro. These results provide evidence of the existence of an alternative S1P lyase.     

An update on sphingosine-1-phosphate receptor 1 modulators

Sphingolipids represent an essential class of lipids found in all eukaryotes, and strongly influence cellular signal transduction. Autoimmune diseases like asthma and multiple sclerosis (MS) are mediated by the sphingosine-1-phosphate receptor 1 (S1P₁) to express a variety of symptoms and disease patterns. Inspired by its natural substrate, an array of artificial sphingolipid derivatives has been developed to target this specific G protein-coupled receptor (GPCR) in an attempt to suppress autoimmune disorders. FTY720, also known as fingolimod, is the first oral disease-modifying therapy for MS on the market. In pursuit of improved stability, bioavailability, and efficiency, structural analogues of this initial prodrug have emerged over time. This review covers a brief introduction to the sphingolipid metabolism, the mechanism of action on S1P₁, and an updated overview of synthetic sphingosine S1P₁ agonists.     

Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5'-phosphate binding domain exposed to the cytosol

Sphingosine-1-phosphate (S1P) is a sphingolipid metabolite that functions as a bioactive lipid molecule. S1P is degraded either by S1P lyase or by S1P phosphohydrolase. The gene encoding mammalian S1P lyase, SPL, has been identified. Here, we characterize the SPL protein in its expression, localization, and topology. The expression levels of the SPL protein correlated well with the dihydrosphingosine-1-phosphate (DHS1P) lyase activity in most tissues. However, liver and heart exhibited high DHS1P lyase activities compared to their SPL protein levels. The SPL mRNA expression was temporally regulated during mouse embryonal development. Immunofluorescence microscopy demonstrated that SPL is localized at the endoplasmic reticulum. Proteinase K digestion studies revealed that the large hydrophilic domain, containing the active site, faces the cytosol. This active site orientation is opposite to that of S1P phosphohydrolase, indicating that the degradation of S1P by two S1P-degrading enzymes occurs in spatially separated sides of the endoplasmic reticulum.     

Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice

Sphingosine-1-phosophate, generated from the phosphorylation of sphingosine by sphingosine kinase enzymes, is suggested to function as an intracellular second messenger for inflammatory mediators, including formyl peptide, C5a, and Fc. More recently, a role for sphingosine kinases during inflammation has also been proposed. Here we show that sphingosine kinase 1 knockout mice exhibit normal inflammatory cell recruitment during thioglycollate-induced peritonitis and that sphingosine kinase 1-null neutrophils respond normally to formyl peptide. In the collagen-induced arthritis model of rheumatoid arthritis, sphingosine kinase 1 knockout mice developed arthritis with normal incidence and severity. Our findings show that sphingosine kinase 1 is dispensable for inflammatory responses and support the need for more extensive studies of sphingosine kinases in inflammation.     

A rapid radioassay for sphingosine kinase

A solvent-extraction-based radioassay for measuring sphingosine kinase (SKase) activity has been developed. The assay utilizes [3H]sphingosine substrate and differentially extracts the [3H]sphingosine-1-phosphate product. The extracted radioactivity is demonstrated to be primarily [3H]sphingosine-1-phosphate with less than 1% contamination by [3H]sphingosine. When assaying SKase activity in the soluble cell fraction, the extraction efficiency of the labeled sphingosine-1-phosphate product is a reproducible 78%, which allows for a simple back calculation to correct for the 22% extraction loss. With minor modification, the assay is also a reproducible procedure for determining SKase activity in subcellular membrane fractions. The assay is far more rapid than thin-layer chromatography and high-performance liquid chromatography methods, which makes it possible to do a large number of assays in a short period of time. The utility of the assay is demonstrated by using it to conduct a complete bisubstrate kinetic analysis of rat heart SKase.     

Synthesis of fluorinated agonist of sphingosine-1-phosphate receptor 1

The bioactive metabolite sphingosine-1-phosphate (S1P), a product of sphingosine kinases (SphKs), mediates diverse biological processes such as cell differentiation, proliferation, survival and angiogenesis. A fluorinated analogue of S1P receptor agonist has been synthesized by utilizing a ring opening reaction of oxacycles by a lithiated difluoromethylphosphonate anion as the key reaction. In vitro activity of this S1P analogue is also reported.     

A benzo[b]thiophene-based selective type 4 S1P receptor agonist

S1P receptors (S1PR1-5) are a group of GPCRs activated by a high affinity binding with S1P that have important roles in the regulation of the immune system. A potent S1PR agonist FTY720 is an immunomodulator used to treat multiple sclerosis and several ‘second generation’ drugs are under clinical development. Subtype-selective agonists have been reported for each S1PR isotype, some of which are used as pharmacological tools for functional studies. Here we report the discovery and initial characterization of compound 5c, a benzo[b]thiophene amino carboxylate which exhibits potent and selective agonist activity for S1PR4. Compound 5c has an EC₅₀ = 200 nM as an agonist in GTPγ³⁵S binding assay for S1PR4 and exhibits no activity against S1PR1,2,3,5. We confirmed its potent activity and decent S1PR subtype selectivity using biochemical and cellular assays.     

To stay or to leave: Stem cells and progenitor cells navigating the S1P gradient

Most hematopoietic stem progenitor cells (HSPCs) reside in bone marrow (BM), but a small amount of HSPCs have been found to circulate between BM and tissues through blood and lymph. Several lines of evidence suggest that sphingosine-1-phosphate (S1P) gradient triggers HSPC egression to blood circulation after mobilization from BM stem cell niches. Stem cells also visit certain tissues. After a temporary 36 h short stay in local tissues, HSPCs go to lymph in response to S1P gradient between lymph and tissue and eventually enter the blood circulation. S1P also has a role in the guidance of the primitive HSPCs homing to BM in vivo, as S1P analogue FTY720 treatment can improve HSPC BM homing and engraftment. In stress conditions, various stem cells or progenitor cells can be attracted to local injured tissues and participate in local tissue cell differentiation and tissue rebuilding through modulation the expression level of S1P1, S1P2 or S1P3 receptors. Hence, S1P is important for stem cells circulation in blood system to accomplish its role in body surveillance and injury recovery.